AB-Biotics and Laboratorios Rubió sign agreement to distribute Neurofarmagen TDAH® in Spain
Neurofarmagen TDAH® is a genetic analysis that allows doctors to see how a patient will react to the most common attention deficit and hyperactivity disorder drugs and helps evaluate future risks.
Biotech company AB-Biotics has signed an agreement with Laboratorios Rubió, granting them exclusive distribution rights in Spain for Neurofarmagen TDAH®. This genetic analysis allows doctors to see how a patient will respond to the most common drugs used to treat attention deficit hyperactivity disorder (ADHD) as well as evaluating the genetic risk of suffering from this disorder in the future.
“The contract will mean a turnover of at least 1.5 million euros for the 2011-2013 period in the Spanish market alone", explained Miquel Àngel Bonachera and Sergi Audivert, co-founders and CEOs of the company. The agreement initially covered only the national market but AB-Biotics has also given Laboratorios Rubió the preferential option to exclusive distribution rights for Germany, the Netherlands, the United Kingdom, Denmark, Argentina, Canada, New Zealand, Brazil and Mexico. For Laboratorios Rubió this agreement will notably increase their global turnover both on a national and international level.
A disorder with a strong genetic component
Attention deficit hyperactivity disorder (ADHD) is one of the most common behavioral alterations, appearing in nearly 5% of children and 3% of adults. This disorder is more frequently found in men than in women and currently accounts for up to 40% of all psychiatric visits by children and young people. ADHD is characterized by moderate to severe distraction, short attention span, restlessness, emotional instability and impulsive behavior. It also has a strong genetic component and is the most commonly inherited behavioral disorder.
Currently, three types of genes are known to be related to ADHD: genes associated with the risk of ADHD in both children and adults (susceptibility); genes associated with tolerance to treatment (pharmacogenetics); and genes associated with pathologies and behavioral alterations that often appear in conjunction with ADHD (comorbidity), like alcoholism, drug addiction, antisocial personality and autism.
Therefore, Neurofarmagen TDAH® analyses all three gene types, allowing a patient to know their risk of suffering from ADHD in the future (for children with a family history of the disorder) or, in the case of those who have already been diagnosed, identify the most appropriate treatment based on their genetic characteristics and evaluate their risk of suffering from associated disorders.